MedPath

HI-Q MARINE BIOTECH INTERNATIONAL LTD.

🇹🇼Taiwan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:2
Phase 2:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (40.0%)
Phase 1
2 (40.0%)
Phase 2
1 (20.0%)

A Randomized, Double-blind Study to Evaluate the Clinical Effect and Safety of Fucoidan in Patients With Squamous Cell Carcinomas of the Head and Neck

Phase 2
Recruiting
Conditions
Squamous Cell Carcinomas of the Head and Neck
First Posted Date
2020-10-22
Last Posted Date
2024-03-05
Lead Sponsor
Hi-Q Marine Biotech International, Ltd.
Target Recruit Count
119
Registration Number
NCT04597476
Locations
🇨🇳

National Taiwan University Hospital, Taipei county, Taiwan

Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC)

Not Applicable
Terminated
Conditions
Advanced Hepatocellular Carcinoma
First Posted Date
2019-08-26
Last Posted Date
2025-01-13
Lead Sponsor
Hi-Q Marine Biotech International, Ltd.
Target Recruit Count
87
Registration Number
NCT04066660
Locations
🇨🇳

Fudan University Zhongshan Hospital, Shanghai, China

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

Not Applicable
Withdrawn
Conditions
NSCLC Stage IV
NSCLC, Stage III
First Posted Date
2017-04-27
Last Posted Date
2019-08-28
Lead Sponsor
Hi-Q Marine Biotech International, Ltd.
Registration Number
NCT03130829
Locations
🇨🇳

Shuang Ho Hospital, New Taipei City, Taiwan

🇨🇳

Wan-Fang Hospital, Taipei, Taiwan

🇨🇳

Taipei Medical University Hospital, Taipei, Taiwan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.